Oral health conditions in patients under antiresorptive therapy are comparable to unexposed during supportive periodontal care.

OBJECTIVES: To investigate oral health and oral health-related quality of life (OHRQoL) of patients under antiresorptive therapy (ART) during supportive periodontal care (SPC) considering history of medication-related osteonecrosis of the jaw (MRONJ). MATERIALS AND METHODS: In this cross-sectional study, 100 patients (50 receiving ART (exposed) and 50 without ART (unexposed)) in regular SPC were enrolled for a clinical oral examination and the evaluation of OHRQoL using the OHIP-G14-questionnaire. History of MRONJ was assessed by anamnesis and reviewing patient records. RESULTS: There were no statistically significant group differences in age (exposed: 70.00 +/- 9.07 versus unexposed: 71.02 +/- 8.22 years), sex, distribution of systemic diseases and duration of SPC (on average 8.61 +/- 5.73 years). Number of teeth (21.02 +/- 5.84 versus 21.40 +/- 5.42), DMFT (18.38 +/- 3.85 versus 17.96 +/- 4.08), probing pocket depth (2.31 +/- 0.20 versus 2.38 +/- 0.26), clinical attachment level (3.25 +/- 0.76 versus 3.46 +/- 0.58) and bleeding on probing (15.07 +/- 11.53 versus 15.77 +/- 13.08) were also not significantly different. The OHIP-G14 sum-score was significantly higher in exposed participants (6.10 +/- 6.76 versus 3.62 +/- 5.22, p = 0.043). History of MRONJ was prevalent in 8% of patients under ART. Periodontal/peri-implant-related MRONJ were reported in three participants with cancer (n = 1 before and n = 2 after active periodontal therapy). History of MRONJ due to endodontic/restorative reasons was reported in one patient with osteoporosis. CONCLUSIONS: Patients under ART in SPC demonstrated similar clinical periodontal and dental status but lower OHRQoL compared to unexposed (not statistically significant). Patient awareness of the MRONJ-risk and appropriate preventive measures should be ensured. CLINICAL RELEVANCE: SPC in osteoporotic patients under ART appeared safe regarding MRONJ, but further investigations on the MRONJ-risk in patients with different risk-profiles are necessary. STUDY REGISTRATION: clinicaltrials.gov (#NCT04192188).